RVTY (Revvity) EBIT per Share : $2.85 (TTM As of Sep. 2024)

View and export this data going back to 1983. Start your Free Trial

What is Revvity EBIT per Share?

Revvity's EBIT per Share for the three months ended in Sep. 2024 was $1.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $2.85.

During the past 12 months, the average EBIT per Share Growth Rate of Revvity was -12.80% per year. During the past 3 years, the average EBIT per Share Growth Rate was -32.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 2.20% per year. During the past 10 years, the average EBIT per Share Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Revvity's EBIT per Share or its related term are showing as below:

RVTY' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -32.2 Med: 8.9 Max: 53.1
Current: -32.2

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Revvity was 53.10% per year. The lowest was -32.20% per year. And the median was 8.90% per year.

RVTY's 3-Year EBIT Growth Rate is ranked worse than
85.47% of 172 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.05 vs RVTY: -32.20

Revvity's EBIT for the three months ended in Sep. 2024 was $125 Mil.

Revvity EBIT per Share Historical Data

The historical data trend for Revvity's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity EBIT per Share Chart

Revvity Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

2.70

7.58

11.19

5.98

2.26

Revvity Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															0.61	0.45	0.48	0.90	1.01

Revvity EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Revvity's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	281.789	/	124.812
=	2.26

Revvity's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	124.74	/	123.026
=	1.01

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.85

Revvity (NYSE:RVTY) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Revvity EBIT per Share Related Terms

Thank you for viewing the detailed overview of Revvity's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Revvity Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

0KHE:UK PKN:Germany PKN:Germany R1VT34:Brazil

Address

940 Winter Street, Waltham, MA, USA, 02451

Website

https://www.revvity.com

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Executives

Prahlad R. Singh	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Tajinder Vohra	officer: Please See Remarks	940 WINTER STREET, WALTHAM MA 02451-1457
Alexis P Michas	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Joel S Goldberg	officer: See Remarks	940 WINTER STREET, WALTHAM MA 02451
Anita Gonzales	officer: Please See Remarks	940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Michelle Mcmurry-heath	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett	director	C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Pascale Witz	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121